CD138 is a protein found on the surface of plasma cells, the immune cells that make antibodies. In medicine, it works as a marker — a kind of molecular flag — that helps pathologists identify plasma cells in tissue samples and helps doctors diagnose certain blood cancers. Its full scientific name is syndecan-1, and it is one of the most widely used tools in blood and bone marrow testing.
What Is CD138 And Why Is It A Key Diagnostic Marker?
CD138 is a protein that sits on the outer surface of cells. It belongs to a family of proteins called syndecans, which help cells interact with their surroundings and with each other. The “CD” in its name stands for “cluster of differentiation” — a naming system scientists use to label proteins on cell surfaces.
What makes CD138 useful is how selective it is. Among the many types of white blood cells, plasma cells carry far more CD138 than almost any other cell in normal blood and bone marrow. That selectivity is what turns a surface protein into a diagnostic marker. When a pathologist sees a cell glowing brightly for CD138 on a lab test, it is a strong signal that the cell is a plasma cell or came from one.
Plasma cells matter because they are the cells that produce antibodies. They are the final stage of B-cell development. When your body fights an infection, some B-cells mature into plasma cells that pump out antibodies targeted at that specific threat. CD138 helps identify these cells at every stage of that process, both in health and in disease.
How Is CD138 Used In Diagnosing Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells. Because myeloma cells are plasma cells, they almost always carry CD138 on their surface. That makes CD138 one of the primary markers pathologists look for when they examine a bone marrow sample for suspected myeloma.
The testing usually happens in two main ways. In immunohistochemistry, a thin slice of bone marrow tissue is treated with a special stain that binds to CD138. Plasma cells then appear as distinctly colored cells under a microscope, and the pathologist can see how many there are and how they are arranged. In flow cytometry, cells from a bone marrow or blood sample are passed one by one through a machine that reads surface proteins. CD138 helps the machine pick out plasma cells from the millions of other cells present.
Doctors combine CD138 with other markers to get a fuller picture. A plasma cell that is cancerous often shows a distinctive pattern — high CD138 alongside markers like CD38, and usually low or absent CD19 and CD45. This combination helps distinguish myeloma cells from normal plasma cells, which matters because the two behave very differently.
One clarification worth knowing: CD138 is not unique to cancer. Normal, healthy plasma cells also carry it. So a positive CD138 result does not by itself mean cancer. It means plasma cells are present. Whether those cells are normal or abnormal depends on how many there are, how they look, and what other markers they carry.
What Other Conditions And Cancers Show CD138?
CD138 is not limited to myeloma. Because it appears on plasma cells generally, it can show up in any condition where plasma cells accumulate.
- Plasma cell disorders. Conditions like monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma involve abnormal plasma cells that carry CD138 but do not yet cause the damage seen in active myeloma.
- Plasmacytoma. A single tumor made of plasma cells, usually found in bone or soft tissue, also tests positive for CD138.
- Lymphomas with plasma cell features. Some lymphomas, including certain marginal zone and lymphoplasmacytic lymphomas, contain cells that express CD138.
- Chronic inflammation. Tissues with ongoing inflammation can contain many normal plasma cells, all CD138-positive, without any cancer being present.
- Other cancers. A small number of non-blood cancers, including some carcinomas, can show CD138 staining, though this is less common.
Because CD138 appears in so many settings, pathologists never rely on it alone. It is one piece of a panel — a group of markers read together to reach an accurate diagnosis.
How Is The CD138 Test Performed?
Testing for CD138 requires a sample of tissue or cells, most often from bone marrow. A doctor collects this through a bone marrow biopsy or aspiration, usually from the hip bone. The sample then goes to a pathology lab, where it is processed in one of two ways.
For immunohistochemistry, the tissue is fixed, sliced very thin, and placed on a slide. A stain that binds specifically to CD138 is applied. Cells carrying the protein take up the stain and become visible under a microscope. This method shows where the plasma cells are located within the bone marrow structure, which flow cytometry cannot do.
For flow cytometry, the sample is treated with antibodies attached to fluorescent tags that stick to CD138 and other markers. The cells flow single file past a laser, and the machine records which markers each cell carries. This method can count large numbers of cells quickly and identify subtle differences between cell types.
Both methods have strengths. Immunohistochemistry preserves the architecture of the tissue. Flow cytometry gives precise counts and detailed marker information. Many clinical teams use both when evaluating a suspected plasma cell disorder.
What Does A Positive Or Negative CD138 Result Mean?
A positive result means plasma cells are present in the sample. That is the only thing CD138 positivity directly tells you. It does not confirm cancer, and it does not measure how advanced any disease is.
A negative result means few or no plasma cells were detected by that marker. In a healthy person, plasma cells make up only a small fraction of bone marrow cells, so a low or absent CD138 signal can be entirely normal.
Interpreting the result always depends on context. The pathologist considers the percentage of plasma cells, whether they are clustered or spread out, what other markers they carry, and what the patient’s blood tests and symptoms show. A high percentage of plasma cells with an abnormal marker pattern points toward a plasma cell disorder. A modest number of normal-looking plasma cells may simply reflect the immune system doing its job.
This is why CD138 results are never read in isolation. They are one part of a diagnostic workup that includes blood tests, imaging, and sometimes genetic testing of the cells themselves.
Why Does CD138 Matter Beyond Diagnosis?
CD138 has uses beyond identifying plasma cells. Because it is so characteristic of myeloma cells, researchers have studied it as a possible target for treatment. The idea is to deliver therapy to cells that carry the marker while sparing cells that do not.
This line of research has had mixed results. CD138 is also shed from the surface of cells into the bloodstream, and this shedding can complicate efforts to target it reliably. Some experimental therapies have aimed at CD138, but as of now, the treatments most commonly used for multiple myeloma target different markers. No CD138-directed therapy is currently a standard first-line treatment.
CD138 also has a role in monitoring. In some settings, doctors track plasma cell numbers over time to see how a disease is responding to treatment. Changes in CD138-positive cell counts can contribute to that picture, though they are interpreted alongside other tests.
One non-obvious point: CD138 is not just a passive label. The protein itself does things. It helps plasma cells stick to the bone marrow environment and supports their survival. That biological role is part of why it is expressed so strongly on these cells, and it is part of why scientists remain interested in it as a potential target.
What CD138 Does Not Tell You
It is worth being clear about the limits. CD138 cannot, on its own:
- Distinguish between normal plasma cells and cancerous ones
- Confirm a diagnosis of multiple myeloma
- Measure how far a disease has progressed
- Predict how a person will respond to treatment
Each of those questions requires additional information — other markers, cell counts, imaging, and clinical findings. CD138 is a starting point, not an answer. Treating it as more than that can lead to confusion, both for patients reading their own reports and for anyone interpreting results without the full context.
Frequently Asked Questions
What does it mean if CD138 is positive?
A positive CD138 result means plasma cells are present in the sample. It does not by itself mean cancer, since normal plasma cells also carry this marker.
Is CD138 a cancer marker?
CD138 is a plasma cell marker, not a cancer marker in the strict sense. It appears on both healthy and cancerous plasma cells, so it helps identify cell type rather than confirming malignancy.
Can CD138 be found in healthy people?
Yes. Healthy people have plasma cells, and those cells carry CD138. A normal bone marrow sample can show CD138-positive cells without any disease being present.
What is the difference between CD138 and CD38?
Both are proteins found on plasma cells, and both are used in testing. CD38 appears on a wider range of immune cells, while CD138 is more selective for plasma cells, so the two are often used together.

